Asclera: New Vein Treatment Just FDA Approved!

For those suffering from spider veins and small varicose veins, there’s a new treatment on the horizon offering excellent results to a wide range of patients with cosmetic vein concerns. Used widely in Europe for over 40 years, Asclera was FDA approved in March 2010 for use in the United States.

Asclera, or polidocanol, is an agent which is injected directly into problem veins, causing the veins to close. The drug has been shown to be especially effective in the treatment of difficult-to-manage spider veins and small varicose veins. Problematic veins occur when the tiny valves inside the blood vessels malfunction, disrupting the normal flow of blood through the vessels. When the flow is disrupted, veins can swell and bulge, becoming visible.

Asclera treatments are a fast and easy way to address cosmetic vein concerns. After the treatment area is prepared, Asclera is injected directly into problem veins. An advantage to using Asclera as an injectable sclerosant is that the active ingredient, Polidocanol, has anesthetic properties, which can make Asclera a less painful treatment option for patients. After patients receive Asclera injections, they can typically return to their daily activities right away. Results are evident in one to three treatment sessions.

Asclera is very well tolerated among patients, and has been used successfully in over 5 million patients seeking relief from venous conditions. Look for more information about this new vein treatment option in the coming months.